Morgan Stanley raised the firm’s price target on Illumina (ILMN) to $105 from $100 and keeps an Equal Weight rating on the shares. The company’s Q2 earnings beat estimates on strong margins and its clinical adoption momentum is encouraging, the analyst tells investors in a research note. However, the firm points out Illumina’s research end market remained muted in the quarter on budget constraints.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ILMN:
- Illumina price target raised to $110 from $105 at Stephens
- Illumina’s Strategic Positioning and Growth Potential Justify Buy Rating Despite Challenges
- Illumina’s Earnings Call: Strategic Gains Amid Challenges
- Illumina price target raised to $126 from $118 at RBC Capital
- Illumina price target raised to $110 from $98 at UBS